Journal
SEMINARS IN FETAL & NEONATAL MEDICINE
Volume 22, Issue 6, Pages 383-390Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.siny.2017.11.002
Keywords
Congenital diaphragmatic hernia; Prenatal therapy; Pulmonary hypoplasia; Pulmonary hypertension; Sildenafil
Categories
Funding
- GOSH Children's Charity
- Engineering and Physical Sciences Research Council [NS/A000027/1]
- Innovative Engineering for Health - Wellcome Trust [WT101957]
- UCL/UCLH NIHR Biomedical Research Centre [IS-BRC-1215-20012]
- GOSHCC
- GOSH NIHR Biomedical Research Centre's funding scheme
- Catapult Cell Therapy
- Fetal Health Foundation (USA) [ZKD2426, O6510]
- Sparks
- Erasmus + Programme of the European Commission [2013-0040]
- CDHUK
- National Institute for Health Research [RP_2014-04-046] Funding Source: researchfish
Ask authors/readers for more resources
Congenital diaphragmatic hernia is surgically correctable, yet the poor lung development determines mortality and morbidity. In isolated cases the outcome may be predicted prenatally by medical imaging. Cases with a poor prognosis could be treated before birth. However, prenatal modulation of lung development remains experimental. Fetoscopic endoluminal tracheal occlusion triggers lung growth and is currently being evaluated in a global clinical trial. Prenatal transplacental sildenafil administration may in due course be a therapeutic approach, reducing the occurrence of persistent pulmonary hypertension, either alone or in combination with fetal surgery. (C) 2017 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
